BOULDER, Colo.--(BUSINESS WIRE)--
Array BioPharma Inc. (Nasdaq: ARRY) today announced that clinical
data will be presented on its p38 inhibitor, ARRY-797 and its MEK
inhibitor, ARRY-162, at the 2008 ACR/ARHP Annual Scientific Meeting in
San Francisco, Calif.
Title: Potent Clinical Anti-inflammatory and Analgesic Activity of
a Novel p38(alpha) Inhibitor ARRY-797 (Poster: 357)
Presenter: Ann E. Remmers, Director, Clinical Science - Pain and
Supportive Care, Array BioPharma
Date: Sunday, October 26, 2008, poster session, 9 - 11 a.m. P.T.
Title: ARRY-162, A Novel MEK Inhibitor: Results of a 14-Day Phase
1a Study in Healthy Subjects and a 28-Day Phase 1b Study
in Rheumatoid Arthritis patients (Poster: 358)
Presenter: Laura Carter, Research Investigator, Array BioPharma
Date: Sunday, October 26, 2008, poster session, 9 - 11 a.m. P.T.
Title: ARRY-797, A Novel p38 MAP Kinase Inhibitor: Results of a
14-Day Phase 1 Study (Poster: 359)
Presenter: Laura Carter, Research Investigator, Array BioPharma
Date: Sunday, October 26, 2008, poster session, 9 - 11 a.m. P.T.
The posters will be available as PDFs after they are presented on
Array's website:
http://www.arraybiopharma.com/PatentsPublications/Default.asp?
PBCategoryID=3 (Due to its length, this URL may need to be
copied/pasted into your Internet browser's address field. Remove the
extra space if one exists.).
About Array BioPharma:
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small
molecule drugs to treat patients afflicted with cancer, inflammatory
and metabolic diseases. Our proprietary drug development pipeline
includes clinical candidates that are designed to regulate
therapeutically important target proteins and are aimed at significant
unmet medical needs. In addition, leading pharmaceutical and
biotechnology companies collaborate with Array to discover and develop
drug candidates across a broad range of therapeutic areas. For more
information on Array, please go to www.arraybiopharma.com.
Source: Array BioPharma Inc.
